Ribomic: Notice regarding personnel changes

Apr 1 02:30 ET

Ribomic: Notice regarding termination of license agreement with Fujimoto Pharmaceutical Co., Ltd.

Mar 31 02:30 ET

Ribomic: Notice of termination of social cooperation course establishment agreement and joint research agreement with the University of Tokyo

Mar 31 02:30 ET

Ribomic: Announcement of joint research results and termination of joint research agreement with Hokkaido University on ANCA-related vasculitis

Mar 27 02:30 ET

Ribomic: Announcement of a joint application with Waseda University based on the results of the JST/CREST “AI Aptamer Drug Discovery Project”

Mar 17 02:30 ET

Ribomic: Notice of patent assessment in Japan for substance patents related to anti-TGF-beta1 aptamers

Mar 13 02:30 ET

Ribomic: Notice of development of kinetic extension technology using antibody Fc region fusion in joint research and development with Ajinomoto Co., Ltd. and completion of patent applications

Mar 11 02:30 ET

Ribomic: Presentation materials at Fusion Conference 2025

Feb 20 01:30 ET

Ribomic: Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31 2024(Based on Japanese GAAP)

Feb 12 01:30 ET

Ribomic: Notice regarding the recording of non-operating income (foreign exchange profit)

Feb 12 01:30 ET

Ribomic: Effectiveness of starting treatment immediately after birth in achondroplasia: paper presented in animal models

Feb 11 22:15 ET

Ribomic: Development of chikungunya virus inhibitor aptamers and publication of papers

Feb 7 01:30 ET

Ribomic: Announcement of the presentation on low dose group response in the Phase II clinical trial of an achondroplasia treatment drug (umedaptanib pegol) at Fusion Conference 2025

Feb 6 01:30 ET

Ribomic: Notice regarding mass exercise of the 17th Stock Acquisition Rights (with exercise price amendment clause), monthly exercise status, and completion of exercise of rights

Jan 27 02:00 ET

Ribomic: Notice Concerning Mass Exercise of the 17th Stock Acquisition Rights (with Exercise Price Amendment Clauses)

Jan 8 01:30 ET

Ribomic: Notice of creation of a cosmetic ingredient candidate “anti-neutrophil elastase aptamer” due to joint research and development with Mitsubishi Corporation Life Sciences Co., Ltd., and completion of a joint patent application

Jan 7 01:35 ET

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Jan 6 01:30 ET

Ribomic: Notice of completion of the observation period for the final case in the first phase II observational trial of an achondroplasia treatment drug (umedaptanib pegol)

Dec 25, 2024 01:30 ET

Ribomic: Dengue virus inhibitors: development of aptamer-siRNA complex “chimeric nucleic acid”

Dec 24, 2024 01:30 ET

Ribomic: A transcript of our financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3 was published on Logme Finance

Dec 3, 2024 01:30 ET